DCT

2:26-cv-08996

Merck Sharp & Dohme LLC v. Apotex Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-08996, D.N.J., 07/20/2026
  • Venue Allegations: Plaintiff alleges venue is proper because Apotex Inc. is a foreign corporation subject to personal jurisdiction in the district, Apotex Corp. conducts purposeful business in New Jersey, and both entities have previously litigated in the district, allegedly consenting to venue.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of the insomnia drug BELSOMRA® (suvorexant) constitutes an act of infringement of four U.S. patents covering the drug's active ingredient and its specific solid dosage formulation.
  • Technical Context: The technology involves both the chemical compound suvorexant, an orexin receptor antagonist, and pharmaceutical formulation techniques, such as amorphous solid dispersions created by hot melt extrusion, used to improve the bioavailability of poorly soluble drugs.
  • Key Procedural History: This action was triggered by Defendants' submission of ANDA No. 221536 and a corresponding Notice of Paragraph IV Certification to Plaintiff, signaling Defendants' intent to market a generic suvorexant product before the expiration of the patents-in-suit. The complaint notes that U.S. Patent No. 12,599,610 is subject to a terminal disclaimer over U.S. Patent Nos. 10,098,892 and 11,980,623, which may link their enforceable terms.

Case Timeline

Date Event
2006-12-01 U.S. Patent 7,951,797 Priority Date
2011-05-31 U.S. Patent 7,951,797 Issued
2012-05-31 U.S. Patents 10,098,892, 11,980,623, and 12,599,610 Priority Date
2018-10-16 U.S. Patent 10,098,892 Issued
2024-05-14 U.S. Patent 11,980,623 Issued
2026-04-14 U.S. Patent 12,599,610 Issued
2026-06-05 Apotex Notice Letter Sent
2026-07-20 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,951,797 - "Substituted Diazepan Orexin Receptor Antagonists"

  • Patent Identification: U.S. Patent No. 7,951,797, "Substituted Diazepan Orexin Receptor Antagonists," issued May 31, 2011 Compl. ¶34
  • The Invention Explained:
    • Problem Addressed: The patent background describes the role of orexin neuropeptides in regulating physiological processes including sleep and wakefulness, suggesting that antagonizing orexin receptors could be a therapeutic approach for treating disorders like insomnia '797 Patent, col. 1:10-19
    • The Patented Solution: The invention provides a class of novel chemical compounds, specifically substituted diazepans, that function as orexin receptor antagonists '797 Patent, abstract The patent claims the compounds themselves, including the specific compound suvorexant, and their use in treating a range of neurological and psychiatric disorders '797 Patent, col. 2:35-43
    • Technical Importance: This invention provided a new chemical entity targeting the orexin system, a novel mechanism of action for treating sleep disorders distinct from previous generations of hypnotics.
  • Key Claims at a Glance:
    • The complaint alleges infringement of at least one claim Compl. ¶52 While not specified, independent claim 1 defines the genus of compounds, and dependent claim 8 recites the specific compound suvorexant.
    • Independent Claim 1, a Markush claim, covers a chemical structure with variable substituent groups, including:
      • A phenyl group (R¹)
      • A central diazepan core
      • A heteroaryl group (R²)
    • The complaint reserves the right to assert additional claims Compl. ¶52

U.S. Patent No. 10,098,892 - "Solid Dosage Formulations of an Orexin Receptor Antagonist"

  • Patent Identification: U.S. Patent No. 10,098,892, "Solid Dosage Formulations of an Orexin Receptor Antagonist," issued October 16, 2018 Compl. ¶35
  • The Invention Explained:
    • Problem Addressed: The patent abstract indicates that the invention is directed at improving the formulation of suvorexant. The technical challenge, common for many modern drugs, is poor aqueous solubility, which can limit oral bioavailability and therapeutic effectiveness '892 Patent, abstract
    • The Patented Solution: The invention is a pharmaceutical composition where suvorexant is molecularly dispersed in a "concentration-enhancing polymer" to create a stable "amorphous dispersion" '892 Patent, abstract This formulation prevents the drug from crystallizing, thereby increasing its solubility upon ingestion '892 Patent, col. 3:15-28 The patent specifically claims compositions made using a hot melt extrusion (HME) process with copovidone as the polymer '892 Patent, claim 1 The '892 patent's FIG. 1 shows an X-ray powder diffraction pattern characteristic of an amorphous material, lacking the sharp peaks associated with a crystalline structure, which supports the patent's description of an amorphous dispersion '892 Patent, Ex. 2, FIG. 1
    • Technical Importance: Creating amorphous solid dispersions via HME is a critical manufacturing technology that enables the oral delivery of poorly soluble compounds like suvorexant.
  • Key Claims at a Glance:
    • The complaint alleges infringement of at least one claim Compl. ¶61 Independent claim 1 is representative.
    • Independent Claim 1 consists of three primary elements:
      • A pharmaceutical composition comprising suvorexant in an amorphous form;
      • and copovidone;
      • wherein the composition is prepared by a process comprising hot melt extrusion of a mixture of suvorexant and copovidone.
    • The complaint reserves the right to assert additional claims Compl. ¶61

U.S. Patent No. 11,980,623 - "Solid Dosage Formulations of an Orexin Receptor Antagonist"

  • Patent Identification: U.S. Patent No. 11,980,623, "Solid Dosage Formulations of an Orexin Receptor Antagonist," issued May 14, 2024 Compl. ¶36
  • Technology Synopsis: As a continuation of the '892 patent, this patent also addresses the problem of suvorexant's poor solubility '623 Patent, abstract It claims a pharmaceutical composition of suvorexant as an amorphous solid dispersion, but its claims specify a polymer selected from a group including copovidone and others, and also recite specific dosage strengths '623 Patent, claim 1
  • Asserted Claims: The complaint asserts at least one claim, with independent claim 1 being representative Compl. ¶69
  • Accused Features: The accused features are the composition of Defendants' generic suvorexant product, which is alleged to be therapeutically equivalent to Merck's BELSOMRA® and thus contain suvorexant in an amorphous dispersion with a polymer '623 Patent, claim 1 Compl. ¶67

U.S. Patent No. 12,599,610 - "Solid Dosage Formulations of an Orexin Receptor Antagonist"

  • Patent Identification: U.S. Patent No. 12,599,610, "Solid Dosage Formulations of an Orexin Receptor Antagonist," issued April 14, 2026 Compl. ¶37
  • Technology Synopsis: This patent, also in the same family as the '892 and '623 patents, is directed to solid dosage formulations of suvorexant '610 Patent, abstract The claims are directed to a composition prepared by hot melt extrusion comprising specific categories of components, including suvorexant, a concentration-enhancing polymer, and other excipients '610 Patent, claim 1 The complaint notes this patent is subject to a terminal disclaimer over the '892 and '623 patents Compl. ¶41
  • Asserted Claims: The complaint asserts at least one claim, with independent claim 1 being representative Compl. ¶77
  • Accused Features: The composition and manufacturing process of Defendants' generic suvorexant tablets are alleged to infringe Compl. ¶73 Compl. ¶75

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendants' proposed generic suvorexant tablets, for which Abbreviated New Drug Application (ANDA) No. 221536 was filed with the U.S. Food and Drug Administration (FDA) Compl. ¶1 Compl. ¶40
  • Functionality and Market Context: The complaint alleges that the accused product is "pharmaceutically and therapeutically equivalent to Merck's BELSOMRA®" Compl. ¶50 Compl. ¶59 Compl. ¶67 Compl. ¶75 As such, it is a solid oral dosage form intended for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance Compl. ¶38 The infringement alleged is the statutory act of filing the ANDA to seek approval for this generic product prior to the expiration of Plaintiff's patents Compl. ¶48 The complaint does not provide further technical details on the specific composition of Defendants' product, as that information is contained within the confidential ANDA filing.

IV. Analysis of Infringement Allegations

U.S. Patent No. 7,951,797 Infringement Allegations

Claim Element (from Dependent Claim 8) Alleged Infringing Functionality Complaint Citation Patent Citation
5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole The complaint alleges that Defendants' generic product is therapeutically equivalent to BELSOMRA® and therefore contains the active ingredient suvorexant, which is the claimed compound. ¶50 col. 32:30-49
  • Identified Points of Contention:
    • Infringement: The complaint alleges that Defendants' notice letter "did not dispute infringement" of the '797 patent Compl. ¶51 In Hatch-Waxman litigation concerning a generic version of a patented drug, infringement of the compound patent is often not the primary dispute.
    • Validity: The central dispute regarding the '797 patent will likely be a challenge to its validity, where Defendants may argue the claimed compound is obvious or anticipated by prior art.

U.S. Patent No. 10,098,892 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
suvorexant in an amorphous form The complaint alleges Defendants' product is therapeutically equivalent to BELSOMRA®, which is formulated with suvorexant as an amorphous solid dispersion to ensure bioavailability. ¶59 col. 11:42-51
and copovidone The complaint's theory of infringement rests on the allegation that to be bioequivalent, the accused product must use the same formulation, including the polymer copovidone. ¶59 col. 10:52-57
wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone The complaint alleges that because BELSOMRA® is manufactured using a hot melt extrusion process, the accused generic product must also be made by this process to achieve the required therapeutic equivalence. ¶59 col. 9:21-34
  • Identified Points of Contention:
    • Technical Questions: The core of the dispute for the '892 patent will be factual. Has Apotex "designed around" the patent? This raises several questions for the court: Does the accused product use "copovidone" or a different polymer? Does it contain suvorexant in an "amorphous form" as defined by the patent, or is it in a different physical state (e.g., crystalline, or a different amorphous polymorph)? Is the accused product manufactured by "hot melt extrusion" or an alternative process?
    • Scope Questions: The definition of what constitutes an "amorphous form" may become a key issue of claim construction.

V. Key Claim Terms for Construction

For U.S. Patent No. 10,098,892

  • The Term: "amorphous form"
  • Context and Importance: This term is critical because infringement hinges on whether the suvorexant in Defendants' product is in the claimed "amorphous form." Defendants may argue their product contains suvorexant in a different physical state (e.g., a different, non-infringing amorphous polymorph, or a partially crystalline form) that falls outside a proper construction of this term. Practitioners may focus on this term because the physical form of the active ingredient directly impacts bioavailability and is a common area for design-arounds in pharmaceutical patent litigation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification describes the goal of the invention broadly as forming an "amorphous dispersion" where the drug is "generally amorphous or dissolved in the polymer" to increase solubility '892 Patent, col. 8:50-54 This language could support a construction that is not limited to a single, specific amorphous structure.
    • Evidence for a Narrower Interpretation: The patent provides specific analytical data characterizing the amorphous form, including an X-ray powder diffraction (XRPD) pattern showing a characteristic "halo" '892 Patent, FIG. 1 and a modulated differential scanning calorimetry (mDSC) thermogram showing a "single glass transition temperature" '892 Patent, FIG. 2 '892 Patent, col. 12:30-41 A party could argue that "amorphous form" should be construed as being limited to a form that exhibits these specific, disclosed physical properties.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval, Defendants will induce infringement by providing a package insert that will "recommend, suggest, encourage and/or instruct" healthcare professionals and patients to use the generic product in a manner that directly infringes at least one claim of the patents-in-suit Compl. ¶54 Compl. ¶62
  • Willful Infringement: While not explicitly pleading a count for willful infringement, the complaint lays the factual groundwork by alleging Defendants have had "actual knowledge" of the patents since at least the date of their Paragraph IV notice letter, June 5, 2026 Compl. ¶49 Compl. ¶58 Compl. ¶66 For the '610 patent, knowledge is alleged from at least its issue date or its listing in the FDA's Orange Book Compl. ¶74

VII. Analyst's Conclusion: Key Questions for the Case

  • A central question for the formulation patents ('892, '623, and '610) will be one of factual infringement: does the specific formulation disclosed in Defendants' confidential ANDA-including its excipients, the physical form of the suvorexant, and the manufacturing process-fall within the scope of Plaintiff's claims, or have Defendants successfully "designed around" the patents?
  • A second core issue, applicable to all four patents, will be validity. The case will likely involve significant disputes over whether the patents-in-suit are invalid as being anticipated or rendered obvious by the prior art, a standard defense in Hatch-Waxman litigation.
  • Finally, a key legal and factual question will be the construction of the term "amorphous form" in the formulation patents. The outcome of the case may turn on whether the court adopts a broad definition covering any non-crystalline state or a narrower one tied to the specific physical characteristics disclosed in the patent's specification.
Loading Complaint